aXichem presents promising data from clinical study regarding phenylcapsaicin’s impact on serum zonulin levels and improved body weight composition in humans
aXichem AB (publ) (“aXichem”), that develops and markets analogue industrial compounds, presents promising data in a peer reviewed mini review report, published in International Journal of Clinical Skills (2022) 16(7). The mini review has the title “Placebo Controlled Study to Investigate The Relationship Between Lowering Serum Composition Using a Daily Oral Dose of Phenylcapsaicin” . The report